Drug Profile
Research programme: neurodegenerative disease therapies - Rottapharm
Alternative Names: CR-3391; CR-3394Latest Information Update: 25 Feb 2010
Price :
$50
*
At a glance
- Originator Rottapharm
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurological disorders; Parkinson's disease
Most Recent Events
- 01 Mar 2006 Preclinical trials in Neurological disorders in Italy (unspecified route)
- 13 Oct 2005 Preclinical trials in Alzheimer's disease in Italy (unspecified route)